Ann Lab Med 2018; 38(2): 160-164
Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma
Naery Yang, M.D.1, Yeung Chul Mun, M.D.2, Chu-Myong Seong, M.D.2, Hee Jin Huh, M.D.3, and Jungwon Huh, M.D.1
Department of Laboratory Medicine1, College of Medicine, Ewha Womans University, Seoul; Department of Internal Medicine2, College of Medicine, Ewha Womans University, Seoul; Department of Laboratory Medicine3, Dongguk University, Ilsan Medical Center, Goyang, Korea
Corresponding author: Jungwon Huh
Department of Laboratory Medicine, College of Medicine, Ewha Womans University, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea
Tel: +82-2-2650-5320
Fax: +82-2-2650-5091
Co-corresponding author: Hee Jin Huh
Department of Laboratory Medicine, Dongguk University School of Medicine, Ilsan Hospital, 27 Dongguk-ro, Ilsandong-gu, Goyang 10326, Korea
Tel: +82-31-961-7893
Fax: +82-31-961-7902
Received: February 27, 2017; Revised: June 25, 2017; Accepted: October 25, 2017; Published online: March 1, 2018.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In multiple myeloma (MM), hyperdiploidy (HD) is known to impart longer overall survival. However, it is unclear whether coexistent HD ameliorates the adverse effects of known high-risk cytogenetics in MM patients. To address this issue, we investigated the clinicopathological characteristics of HD with high-risk cytogenetics in MM. Ninety-seven patients with MM were included in the study. For metaphase cytogenetics (MC), unstimulated cells from bone marrow aspirates were cultured for either 24 or 48 hours. To detect HD by interphase fluorescence in situ hybridization (iFISH), we assessed trisomies of chromosomes 5, 7, 9, 11, 15, and 17. Of the 97 MM patients, 40 showed HD. The frequency of co-occurrence of HD and high-risk cytogenetics was 14% (14/97). When the clinicopathological characteristics were compared between the two groups of HD with high-risk cytogenetics vs. non-HD (NHD) with high-risk cytogenetics, the level of beta 2 microglobulin and stage distribution significantly differed (P=0.020, P=0.032, respectively). This study shows that some of the clinicopathological characteristics of MM patients with high-risk cytogenetics differ according to HD or NHD status.
Keywords: Hyperdiploidy, Multiple myeloma, Cytogenetics, High risk

This Article



Indexed/Covered by